Stoke Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company can raise money by selling shares at market prices when it needs cash for operations.
Shows the company is preparing to sell shares to investors to raise funds for its business.
Quarterly earnings show whether the company is making progress and managing money wisely.
Quarterly earnings show whether the company is making progress and managing money wisely.
Finishing patient enrollment is a major milestone for drug development that could lead to approval and sales.
Directors make important decisions about company strategy and spending; shareholder votes ensure accountability.
Quarterly earnings show whether the company is making progress and managing money wisely.
Stocky reads Stoke Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Stoke Therapeutics, Inc.'s most recent tracked filing was a 8-K on 3 Aug 2026: Updates controlled equity offering agreement with Cantor Fitzgerald.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.